Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | GJB2 | P29033 | 4/20 | 0.36 |
| ▸ | TNF | P01375 | 1/20 | 0.34 |
| ▸ | GBA1 | P04062 | 1/20 | 0.33 |
| ▸ | PPP5C | P53041 | 1/20 | 0.33 |
| ▸ | PTAFR | P25105 | 1/20 | 0.33 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.31 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10765035 | 1.00 | ALDH1A1 (0.41) | ALDH1A1TDP1SMN1; SMN2GJB2TNF | |
| SCHEMBL5008877 | 1.00 | ALDH1A1 (0.41) | ALDH1A1TDP1SMN1; SMN2GJB2TNF | |
| SCHEMBL12000846 | 0.95 | SMN1; SMN2 (0.41) | ALDH1A1TDP1SMN1; SMN2GJB2TNF | |
| SCHEMBL14580119 | 0.95 | SMN1; SMN2 (0.41) | ALDH1A1TDP1SMN1; SMN2GJB2TNF | |
| SCHEMBL7794269 | 0.91 | ALDH1A1 (0.44) | ALDH1A1TDP1SMN1; SMN2GJB2GBA1 | |
| SCHEMBL7794271 | 0.91 | ALDH1A1 (0.44) | ALDH1A1TDP1SMN1; SMN2GJB2GBA1 | |
| SCHEMBL3979922 | 0.89 | ALDH1A1 (0.40) | ALDH1A1TDP1SMN1; SMN2GJB2TNF | |
| SCHEMBL14440219 | 0.86 | GJB2 (0.40) | ALDH1A1TDP1SMN1; SMN2GJB2TNF | |
| SCHEMBL14440549 | 0.86 | GJB2 (0.40) | ALDH1A1TDP1SMN1; SMN2GJB2TNF | |
| SCHEMBL14440201 | 0.86 | GJB2 (0.40) | ALDH1A1TDP1SMN1; SMN2GJB2TNF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7361745-B2 | Process for the preparation of 1-chloro-3,5-di-o-acyl-2-deoxy-l-ribofuranoside derivatives | INALCO S.P.A. (IT) | 2008-04-22 | — | — | US | claimed |
| US-20070083041-A1 | Process for the preparation of 1-chloro-3,5-di-o-acyl-2-deoxy-l-ribofuranoside derivatives | INALCO, S.P.A. (IT) | 2007-04-12 | — | — | US | claimed |
| EP-1699805-A1 | PROCESS FOR THE PREPARATION OF 1-CHLORO-3,5-DI-O-ACYL-2-DEOXY-L-RIBOFURANOSIDE DERIVATIVES | Inalco S.p.A. (IT) | 2006-09-13 | — | — | EP | claimed |
| WO-2005044832-A1 | PROCESS FOR THE PREPARATION OF 1-CHLORO-3,5-DI-O-ACYL-2-DEOXY-L-RIBOFURANOSIDE DERIVATIVES | INALCO S.P.A. (IT) | 2005-05-19 | — | — | WO | claimed |
| US-7361745-B2 | Process for the preparation of 1-chloro-3,5-di-o-acyl-2-deoxy-l-ribofuranoside derivatives | INALCO S.P.A. (IT) | 2008-04-22 | — | — | US | disclosed |
| US-20070083041-A1 | Process for the preparation of 1-chloro-3,5-di-o-acyl-2-deoxy-l-ribofuranoside derivatives | INALCO, S.P.A. (IT) | 2007-04-12 | — | — | US | disclosed |
| EP-1699805-A1 | PROCESS FOR THE PREPARATION OF 1-CHLORO-3,5-DI-O-ACYL-2-DEOXY-L-RIBOFURANOSIDE DERIVATIVES | Inalco S.p.A. (IT) | 2006-09-13 | — | — | EP | disclosed |
| WO-2005044832-A1 | PROCESS FOR THE PREPARATION OF 1-CHLORO-3,5-DI-O-ACYL-2-DEOXY-L-RIBOFURANOSIDE DERIVATIVES | INALCO S.P.A. (IT) | 2005-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070083041-A1 | Process for the preparation of 1-chloro-3,5-di-o-acyl-2-deoxy-l-ribofuranoside derivatives | RNGTT, RNASEL, CPSF7 | ALDH1A1 953/4885TDP1 1827/4885SMN1; SMN2 2959/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.